Brigitte Calles

As Jean-Luc Delay begins his role as the new Chair of the EFPIA Innovation Board Sponsored Committee (IBSC), he shares his vision to restore Europe’s competitiveness and accelerate patient access to medicines. “I’m honored to step into the role of Chair of EFPIA’s Innovation Board Sponsored Committee. Our collective goal is to ensure Europe remains a global leader in pharmaceutical innovation by championing legislation that accelerates clinical trials and the translation of science into impactful healthcare solutions. We’ll continue working with EU policymakers, fostering inclusive dialogue with innovators, and seizing opportunities like the EU Biotech Act to drive investment, access, and innovation for patients. I look forward to co-developing sustainable solutions that help build a healthier and more competitive Europe.” #WeWontRest

294

13 commentaires

We’re excited to announce that our partner Ipsen received approval from the European Commission for our flagship therapy as a treatment for patients with previously treated advanced #NeuroendocrineTumors (NET).    Learn more: bit.ly/4kZIvMX.

205

8 commentaires

Caroline Ven, CEO of pharma.be calls for a #European #investment commitment in #health, comparable to the one European leaders have agreed on regarding defense spending, in an exclusive interview with Le journal du Médecin & Artsenkrant https://lnkd.in/eTEjERnc #innovation #innovatie #geneesmiddelen #médicaments #vaccins #gezondheid #gezondheidszorg #santé #soinsdesanté #toekomst #future #België #Belgique #Europe #Europa EFPIA - European Federation of Pharmaceutical Industries and Associations

41

Servier and IDEAYA Biosciences, a leading precision medicine oncology company, announced an exclusive license agreement to bring darovasertib, a promising treatment for a rare eye cancer, to patients worldwide. Under the agreement, Servier obtains the regulatory and commercial rights for darovasertib in all territories outside the United States. IDEAYA retains its rights for darovasertib in the United States. Darovasertib, a potent and selective protein kinase C (PKC) inhibitor, is being developed to broadly address primary and metastatic uveal melanoma. Arnaud Lallouette, EVP Global Medical & Patient Affairs at Servier: “At Servier, our mission is to deliver transformative therapies to patients with significant needs. Our collaboration with IDEAYA is a significant step to make darovasertib the potential first-in-class treatment available to uveal melanoma patients worldwide. Today, there are limited treatment options and there is an urgent need to improve patient outcomes. We look forward to leveraging our global oncology network, and expertise in developing oncology targeted therapies, to make this groundbreaking treatment accessible to patients across the globe.” Yujiro S. Hata, President and CEO, IDEAYA Biosciences: “Darovasertib addresses a significant unmet need, and we are thrilled to partner with Servier to globally develop it as a potential standard-of-care for uveal melanoma patients worldwide. This partnership enables IDEAYA and Servier to accelerate the global development for darovasertib across three Phase 3 registrational trials, aiming to improve patient outcomes in the neoadjuvant, adjuvant and metastatic settings.” Daniel Simon, Chief Business Officer, IDEAYA Biosciences: “We believe Servier’s global footprint and proven track record in bringing novel therapies to patients in Europe and other key territories outside of the U.S. will ensure that this potentially life-changing treatment reaches as many patients as possible.” Darovasertib is currently being evaluated in multiple global clinical trials. These include a Phase 2/3 randomized trial evaluating darovasertib in combination with crizotinib in first line patients with HLA-A2-negative metastatic uveal melanoma (UM), for which the median progression free survival readout is anticipated from year-end 2025 to Q1 2026, and a Phase 3 randomized trial evaluating neoadjuvant darovasertib as a monotherapy in primary UM, independent of HLA status. IDEAYA and Servier will target to launch a global Phase 3 randomized clinical trial in 2026 to evaluate adjuvant darovasertib in primary UM, also in both HLA-A2-negative and -positive patients. Under the terms of the agreement, IDEAYA will receive an upfront payment of $210 million, and be eligible for up to $100 million in regulatory approval-based milestone payments and up to $220 million in commercial milestone payments, as well as double-digit royalties on net sales in all territories outside of the US. #IDEAYA #Servier

353

1 commentaire

We are proud to announce that #CUAnschutz will lead a groundbreaking national clinical trial – supported by a $29M grant from Octapharma – to evaluate whether early replacement of fibrinogen, a critical blood clotting mechanism in the body, can improve outcomes for trauma patients experiencing life-threatening bleeding. This study is one of the largest clinical trial grants in campus history, and has the potential to transform how we treat severe bleeding, reduce preventable deaths and save lives in both military and civilian settings. 🗞️

290

🆕 We are proud to partner with the newly launched EASYGEN Consortium – an EU-funded initiative led by Fresenius Group to decentralise CAR-T cell therapy. 💡 The EASYGEN project aims to develop an automated, hospital-based platform for producing personalised CAR-T therapies within days, enhancing patient access, reducing hospital workload, and cutting costs. 🌏 Together with 17 other leading institutions across 8 countries, we’re helping make CAR-T therapy more accessible, as currently fewer than 20% of eligible patients receive it.  As a key partner, EBMT will:  📊 Participate in a study examining current CAR-T treatment processes  📰 Conduct a literature review on the quality of life of patients  💡 Support patient education and advocacy 🔗 Read the Press Release ➡️ https://lnkd.in/dTBHhntz #CART #CellTherapy #EASYGEN #HealthInnovation #PatientAdvocacy Innovative Health Initiative (IHI)

37

1 commentaire